What Is SLU-PP-332? Research Evidence & Profile

What Is SLU-PP-332?

SLU-PP-332 is a synthetic small-molecule agonist reported in the literature for ERRα, ERRβ, and ERRγ research. This page identifies the material as SLU-PP-332, with synonyms SLU-PP-332. The SLU-PP-332 identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Evidence at a Glance

0ClinicalTrials.gov query records

10PubMed query records

6Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for SLU-PP-332 is organized around ERRα, ERRβ, and ERRγ research, nuclear-receptor ligand profiling, small-molecule characterization, and analytical compound workflows. For SLU-PP-332, those subjects define the literature and analytical context of this specific research compound; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / Study	Phase	Status	Context	Last registry update
No exact-match registry records were returned by the displayed query at the retrieval time.

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature6 important records shown

Selected Literature

Selected PubMed record

A Synthetic ERR Agonist Alleviates Metabolic Syndrome.

The Journal of pharmacology and experimental therapeutics · 2024 Jan 17

PMID 37739806

Selected PubMed record

Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.

Circulation · 2024 Jan 16

PMID 37961903

Selected PubMed record

In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential.

Rapid communications in mass spectrometry : RCM · 2026 Apr 30

PMID 41588687

Selected PubMed record

Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.

ACS chemical biology · 2023 Apr 21

PMID 36988910

Selected PubMed record

Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling.

International journal of biological macromolecules · 2026 Apr

PMID 41850449

Selected PubMed record

An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity.

The Journal of pharmacology and experimental therapeutics · 2026 Jan

PMID 41421047

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend: SLU-PP-332
Available Specifications: 5mg, 10mg
Pack Format: 10 Vials
Molecular Formula: C18H14N2O2
Molecular Weight: 290.3 g/mol
Synonyms: SLU-PP-332

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Source: NOVABIO product identity record · No single PubChem record is asserted for this catalogue entry.

Research Tools for SLU-PP-332

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA

Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

SLU-PP-332 Research Summary

Identity

SLU-PP-332; specifications: 5mg, 10mg. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Mechanism

Evidence

0 registry records and 10 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

SLU-PP-332 is represented here by the catalogue identity SLU-PP-332. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation. The product record lists 5mg, 10mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for SLU-PP-332 is organized around ERRα, ERRβ, and ERRγ research, nuclear-receptor ligand profiling, small-molecule characterization, and analytical compound workflows. For SLU-PP-332, those subjects define the literature and analytical context of this specific research compound; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 0 ClinicalTrials.gov records and 10 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

SLU-PP-332 FAQ

What is SLU-PP-332?

What research records are indexed for SLU-PP-332?

The synchronized query returned 0 ClinicalTrials.gov records and 10 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is SLU-PP-332 FDA approved?

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources: ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved: 2026-10-06T12:08:49Z
Inclusion: Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations: Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by: NOVABIO Research
Reviewed date: 2026-10-06
Editorial methodology: How NOVABIO builds Research Profiles
Corrections contact: Contact NOVABIO with the page URL and source record.